|Bid||50.63 x 800|
|Ask||50.91 x 4000|
|Day's Range||50.48 - 51.33|
|52 Week Range||41.45 - 61.71|
|Beta (5Y Monthly)||0.64|
|PE Ratio (TTM)||9.62|
|Earnings Date||Feb 06, 2023 - Feb 10, 2023|
|Forward Dividend & Yield||1.60 (3.23%)|
|Ex-Dividend Date||Nov 03, 2022|
|1y Target Est||54.78|
Shares of Prometheus Biosciences (NASDAQ: RXDX) were down more than 12% this week as of Friday morning, according to data from S&P Global Intelligence. The clinical-stage biotech company specializes in immunotherapies with a focus on inflammatory bowel disease (IBD). Prometheus' lead therapy in its pipeline is IBD drug PRA023.
Roivant Sciences (ROIV), Pfizer's (PFE) new Vant company will take care of funding the global development of RVT-3101 in inflammatory and fibrotic diseases.
Persistence data from a mid-stage study showed that Valneva's (VALN) Lyme disease vaccine elicited antibody levels which remained above baseline six months after completing dose administration in children and adults.